Dramatic response with capecitabine after cranial radiation to the brain parenchymal and leptomeningeal metastases from lung cancer.
It is known that the prognosis of Non Small Cell Lung Cancer with brain metastasis are very poor with a median survival of only a few months. Although some chemotherapeutic agents penetrate the blood brain barrier generally chemotherapy results are bad but efficiency may be better after radiotherapy. For this reason brain metastatic disease requires some efforts to improve the response rate. Here we reported a case with lung cancer metastatic to the brain and we discussed the good response to capecitabine after cranial radiotherapy (C).
Paydas
Semra
S
Cukurova University, Faculty of Medicine, Department of Oncology, Turkey. sepay@cu.edu.tr
Bicakci
Kenan
K
Yavuz
Sinan
S
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D000069287:Capecitabine; D018287:Carcinoma, Large Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary; D018278:Carcinoma, Neuroendocrine / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004502:Education, Medical, Continuing; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology; D008577:Meningeal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary; D008875:Middle Aged; D012074:Remission Induction
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil